18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/ CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in NK/T-cell lymphoma.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors. |
Device: 18F-FDG PET/ CT
18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
|
Outcome Measures
Primary Outcome Measures
- 3 year progression-free survival [up to 3 years after initial diagnosis]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
newly diagnosed NK/T-cell lymphoma
-
treated using an anthracycline-containing regimen
-
minimal follow-up at 6 months after the completion of first-line treatment
-
complete medical history and clinicopathological data
Exclusion Criteria:
-
secondary malignant disease
-
serious infection or inflammation (e.g., HIV)
-
primary central nervous system lymphoma
-
hepatic or renal dysfunction.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Peking University Cancer Hospital | Beijing | Beijing | China | 100142 |
Sponsors and Collaborators
- Peking University Cancer Hospital & Institute
- Beijing Municipal Administration of Hospitals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- XW-NK/T-002